Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission
1. Avidity completed enrollment for the Phase 3 HARBOR trial of del-desiran. 2. Topline data from the trial is expected in Q2 2026. 3. Marketing applications for del-desiran are planned for H2 2026 in multiple regions. 4. Del-desiran targets the genetic cause of myotonic dystrophy type 1 (DM1). 5. No approved drugs currently exist for DM1, highlighting del-desiran's potential impact.